The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Reduced Expression of SMAD4 Is Associated with Poor Survival in Colon Cancer
Open accessPublished version of a preprint
Abstract
Purpose: SMAD4 loss is associated with the development of metastases and poor prognosis. We evaluated expression of SMAD4 protein and its association with tumor characteristics, including biomarkers and outcome in terms of relapse-free survival and overall survival. Experimental design: We used 1,564 stage II/III colon cancer samples from PETACC-3 to evaluate SMAD4 expression by immunohistochemistry. SMAD4 protein expression was validated by assessing mRNA expression using available expression array data. SMAD4 expression was also studied on 34 adenomas and 10 colon cancer liver metastases with their primaries. Loss of SMAD4 immunoreactivity was defined as focal or diffuse. Cases without SMAD4 loss were subdivided into those with strong and weak expression. Results: SMAD4 protein expression was informative in 1,381/1,564 cases. SMAD4 loss was found in 293/1,381 (21%) cases. Of 1,088 cases without SMAD4 loss (79%), 530 showed weak and 558 strong expression. SMAD4 loss occurred also in adenomas, but less extensively than in carcinomas. Liver metastases followed mostly the expression pattern of the primary tumor. SMAD4 loss, including weak expression, identified patients with poor survival in stage II as well as III and in both treatment arms. SMAD4 loss was less frequent in tumors with microsatellite instability and more frequent in those with loss of heterozygosity of 18q. Conclusions: We conclude that clonal loss of SMAD4 expression in adenomas, carcinomas, and liver metastases increases with disease progression. SMAD4 loss, and to a lesser extent weak expression, is strongly associated with poor survival regardless of stage. Clin Cancer Res; 22(12); 3037–47. ©2016 AACR.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Loss of p53 causes defects in DNA damage response and DNA repair, leading to genomic instability [12], whereas loss of SMAD4 impacts cell proliferation and differentiation pathways and is associated with CRC progression [17].”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [17]
Citations
Cites
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Genetic Alterations during Colorectal-Tumor Development
Vogelstein, B., Fearon, E. R., Hamilton, S. R., Kern, S. E., Preisinger, A. C., Leppert, M., Smits, A. M. M., & Bos, J. L. (1988) · New England Journal of Medicine · doi:10.1056/nejm198809013190901 · Cited by 6,728
Smad-dependent and Smad-independent pathways in TGF-β family signalling
Derynck, R., & Zhang, Y. E. (2003) · Nature · doi:10.1038/nature02006 · Cited by 5,373
WHO Classification of Tumours of the Digestive System
Bosman, F. T. (2010) · Medical Entomology and Zoology · Cited by 5,041
Self-citationCunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033025 · Cited by 5,035
Lessons from hereditary colorectal cancer
Kinzler, K. W., & Vogelstein, B. (1996) · Cell · doi:10.1016/s0092-8674(00)81333-1 · Cited by 4,919
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Van Cutsem, E., Köhne, C.-H., Hitre, E., Zaluski, J., Chang Chien, C.-R., Makhson, A., D'Haens, G., Pintér, T., Lim, R., Bodoky, G., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805019 · Cited by 3,877
Self-citationTGF-β signalling from cell membrane to nucleus through SMAD proteins
Heldin, C.-H., Miyazono, K., & ten Dijke, P. (1997) · Nature · doi:10.1038/37284 · Cited by 3,696
Oxaliplatin, Fluorouracil, and Leucovorin as Adjuvant Treatment for Colon Cancer
André, T., Boni, C., Mounedji-Boudiaf, L., Navarro, M., Tabernero, J., Hickish, T., Topham, C., Zaninelli, M., Clingan, P., Bridgewater, J., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032709 · Cited by 3,689
Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer
Saltz, L. B., Cox, J. V., Blanke, C., Rosen, L. S., Fehrenbacher, L., Moore, M. J., Maroun, J. A., Ackland, S. P., Locker, P. K., Pirotta, N., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200009283431302 · Cited by 3,005
Cited by
Transforming Growth Factor-β Signaling Pathway in Colorectal Cancer and Its Tumor Microenvironment
Itatani, Y., Kawada, K., & Sakai, Y. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20235822 · Cited by 240
Adjuvant Chemotherapy for Stage III Colon Cancer
Taïeb, J., & Gallois, C. (2020) · Cancers · doi:10.3390/cancers12092679 · Cited by 134
Wasserman, I., Lee, L. H., Ogino, S., Marco, M. R., Wu, C., Chen, X., Datta, J., Sadot, E., Szeglin, B. C., Guillem, J. G., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1726 · Cited by 119
Targeting the Microenvironment in Advanced Colorectal Cancer
Tauriello, D. V. F., & Batlle, E. (2016) · Trends in cancer · doi:10.1016/j.trecan.2016.08.001 · Cited by 115
Jiang, T., Ye, L., Han, Z., Liu, Y., Yang, Y., Peng, Z., & Fan, J. (2017) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-017-0602-5 · Cited by 99
Metadata
- Authors
- Yan, P., Klingbiel, D., Saridaki, Z., Ceppa, P., Curto, M., McKee, T. A., Roth, A., Tejpar, S., Delorenzi, M., Bosman, F. T., & Fiocca, R.
- Affiliations
- University of Lausanne (CH)
- Swiss Group For Clinical Cancer Research (CH)
- University of Crete (GR)
- Ospedale Policlinico San Martino (IT)
- University Hospital of Geneva (CH)
- Universitair Ziekenhuis Leuven (BE)
- SIB Swiss Institute of Bioinformatics (CH)
- 1Institute of Pathology, University of Lausanne, Lausanne, Switzerland.
- Corresponding author
- Fiocca, Roberto
- Venue
- Clinical Cancer Research
- Published
- 2016-06-14
- Volume
- 22
- Issue
- 12
- Pages
- 3037-3047
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2290450257
- Cited by
- 78
- References
- 55
- Citations by year
- 2026: 6 · 2025: 9 · 2024: 9 · 2023: 4 · 2022: 7 · 2021: 8 · 2020: 9 · 2019: 9 · 2018: 6 · 2017: 6 · 2016: 4
- FWCI
- 7.56
- Type
- journal article
- Language
- en
- Open access
- Licence
- cc-by
- Locations
- Clinical Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- Archive ouverte UNIGE (University of Geneva) (submittedVersion, cc-by)
- CINECA IRIS Institutial Research Information System (University of Genoa) (submittedVersion)
- IRIS (submittedVersion)
- SERVAL (Université de Lausanne) (submittedVersion)
- Funders
- Pfizer
- Hellenic Society of Medical Oncology
- Topics
- Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Mechanisms of cancer metastasis
- Keywords
- SMAD4, colon cancer, protein expression loss, prognostic factors, relapse-free survival, overall survival, liver metastasis, colorectal adenoma, microsatellite instability, disease progression, stage II and III colon cancer
- MeSH terms
- Adenoma, Colonic Neoplasms, Humans, Immunohistochemistry, Liver Neoplasms, Prognosis, RNA, Messenger, Biomarkers, Tumor, Disease Progression, Disease-Free Survival, Smad4 Protein, Microsatellite Instability
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Reduced Expression of SMAD4 Is Associated with Poor Survival in Colon Cancer. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-15-0939
- The paper
- Yan, P., Klingbiel, D., Saridaki, Z., Ceppa, P., Curto, M., McKee, T. A., Roth, A., Tejpar, S., Delorenzi, M., Bosman, F. T., & Fiocca, R. (2016). Reduced Expression of SMAD4 Is Associated with Poor Survival in Colon Cancer. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-15-0939
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.